Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 15 June 2009, doi:10.1136/bmj.b2345
Cite this as: BMJ 2009;338:b2345
| The first 150 words of the full text of this article appear below. |
The potentially harmful effects of non-steroidal anti-inflammatory drugs (NSAIDs) are rarely discussed in the treatment of A/H1N1 flu, which has caused high death rates in Mexico.1 2
Severe and fatal cases, including sudden death, are characterised by severe sepsis with multi-organ failure with findings such as fever, leucocytosis, leucopenia, acute respiratory distress syndrome (ARDS), liver impairment, renal failure, rhabdomyolysis, and hypotension.2 NSAIDs may aggravate these syndromes, leading to multi-organ failure.3
Since the flu pandemics of the 20th century salicylates have been linked to Reyes syndrome and their use restricted in children. But NSAIDs such as diclofenac, mefenamic acid, and ibuprofen are still used as antipyretics in many countries, albeit less often than aspirin. Since the use of diclofenac and mefenamic acid was restricted in children in Japan in 2000, the case fatality of so called flu associated encephalopathy has fallen dramatically.4
Reanalysing the World Health Organizations data on A/H1N1 flu,2 I
Rokuro Hama, chairperson1
1 Japan Institute of Pharmacovigilance, 902 Ueshio3-2-17, Tennoji-ku Osaka, Japan 543-0002
gec00724@nifty.com
Read all Rapid Responses